Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS-Reference-Cited by-同舟云学术

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Published:2017-08 Issue:7666 Volume:548 Page:234-238
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Yao Zhan,Yaeger Rona,Rodrik-Outmezguine Vanessa S.,Tao Anthony,Torres Neilawattie M.,Chang Matthew T.,Drosten Matthias,Zhao Huiyong,Cecchi Fabiola,Hembrough Todd,Michels Judith,Baumert Hervé,Miles Linde,Campbell Naomi M.,de Stanchina Elisa,Solit David B.,Barbacid Mariano,Taylor Barry S.,Rosen Neal

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature23291.pdf

Reference18 articles.

1. Yao, Z. et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28, 370–383 (2015)

2. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004)

3. Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091–1104 (2010)

4. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010)

5. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015)

Cited by 418 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and Biological Concepts in Pediatric High-Grade Gliomas;Cells;2024-09-05

2. A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC;Scientific Reports;2024-09-01

3. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer;Cancer Medicine;2024-09

4. Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells;Cell Reports;2024-09

5. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23